# WEST Search History

DATE: Monday, August 11, 2003

| Set Name side by side | Query | Hit Count | Set Name result set |
|---|---|---|---|
| *DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ* | | | |
| L6 | l1 and l2 and l5 | 29 | L6 |
| L5 | mg or mg. or mg$ | 923753 | L5 |
| L4 | mg or mg. | 834559 | L4 |
| L3 | mg | 834557 | L3 |
| L2 | nocardia or actinosynnema | 3467 | L2 |
| L1 | maytansinoid$ or ansamitocin$ | 172 | L1 |

END OF SEARCH HISTORY

```
            QUE (MAYTANSINOID OR MAYTANSINOIDS OR ANSAMITOCIN OR ANSAMITOCI
                 ---------

     FILE 'CAPLUS, BIOTECHDS, USPATFULL, CANCERLIT, TOXCENTER, USPAT2' ENTERED
     AT 08:40:24 ON 11 AUG 2003
L2            11 S L1
L3             9 DUP REM L2 (2 DUPLICATES REMOVED)

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    40.85      44.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.95      -1.95
```

APLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2
AN 2001:763222 CAPLUS
DN 135:302951
TI Methods for ansamitocin production
IN Fulston, Mark; Stefanska, Anna; Thirkettle, Jan
PA SmithKline Beecham P.L.C., UK
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2001077360 | A2 | 20011018 | WO 2001-GB1661 | 20010411 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2002015984 | A1 | 20020207 | US 2001-828758 | 20010409 |
| | US 6573074 | B2 | 20030603 | | |
| | EP 1272653 | A2 | 20030108 | EP 2001-966770 | 20010411 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | NO 2002004893 | A | 20021010 | NO 2002-4893 | 20021010 |
| PRAI | US 2000-196361P | P | 20000412 | | |
| | WO 2001-GB1661 | W | 20010411 | | |

AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from **Actinosynnema** pretiosum containing 86.3 **mg**/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 **mg**/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation This extract was then dissolved in toluene, loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of **ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins.**
AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from **Actinosynnema** pretiosum containing 86.3 **mg**/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 **mg**/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation This extract was then dissolved in toluene, loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in

toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of **ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins.**

APLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2
AN 2001:763222 CAPLUS
DN 135:302951
TI Methods for ansamitocin production
IN Fulston, Mark; Stefanska, Anna; Thirkettle, Jan
PA SmithKline Beecham P.L.C., UK
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2001077360 | A2 | 20011018 | WO 2001-GB1661 | 20010411 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2002015984 | A1 | 20020207 | US 2001-828758 | 20010409 |
| | US 6573074 | B2 | 20030603 | | |
| | EP 1272653 | A2 | 20030108 | EP 2001-966770 | 20010411 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | NO 2002004893 | A | 20021010 | NO 2002-4893 | 20021010 |
| PRAI | US 2000-196361P | P | 20000412 | | |
| | WO 2001-GB1661 | W | 20010411 | | |

AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from **Actinosynnema** pretiosum containing 86.3 **mg**/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 **mg**/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation This extract was then dissolved in toluene, loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of **ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins.**
AB Improved purification methods for **ansamitocins** are disclosed. Thus, 37 L of fermentation broth from **Actinosynnema** pretiosum containing 86.3 **mg**/L **ansamitocin** P-3 was heat treated in-situ at 75 °C to kill the microorganisms. Forty L of toluene was added and the mixture was heated to 45°C and agitated for 16 h. After the phases had separated, the toluene layer containing 80 **mg**/L **ansamitocin** P-3 was siphoned off and concentrated by evaporation At this point the extract contained 3.1 g of **ansamitocin** P-3 representing a recovery of ~ 97%. The resulting extract was re-dissolved in toluene and concentrated one again by evaporation This extract was then dissolved in toluene, loaded onto a Kieselgel 60 column, and eluted using a 2% methanol in

toluene mobile phase. The **ansamitocin** P-3 fractions were combined and concentrated yielding an 3.2 g of an oily solid containing 2.5 g of **ansamitocin** P-3. This solid was taken up in 200 mL Et acetate, warmed to 40 °C, combined with 200 mL heptane and allowed to cool. Once seeded with pure **ansamitocin** P-3 crystals the crystallization occurred spontaneously. A yield of 2.5 g of crystals was obtained containing 86% (2.15 g) **ansamitocin** P-3 with the remainder consisting mostly of other **ansamitocins.**